

Please type a plus sign (+) inside this box → +

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)				Complete if Known Application Number 10/056,567 Filing Date January 25, 2002 First Named Inventor Shanker GUPTA Group Art Unit 1623 Examiner Name Michael C. Henry Attorney Docket Number 214980	
Sheet	1	of	2		

U.S. PATENT DOCUMENTS						
Examiner Initials	Doc. No.	U.S. Patent Document		Name of Patentee or Applicant	Date of Publication	Filing Date if Appropriate
		Application or Patent Number	Kind Code			
M.C.H.	AH	4,499,082		Shenvi et al.	2/12/85	
	AI	5,106,948		Kinder et al.	4/21/92	
	AJ	5,169,841		Kleeman et al.	12/8/92	
	AK	5,187,157		Kettner et al.	2/16/93	
	AL	5,242,904		Kettner et al.	9/7/93	
	AM	5,250,720		Kettner et al.	10/5/93	
	AN	5,492,900		LaHann	2/20/96	
	AO	5,574,017		Gutheil	11/12/96	
	AP	5,935,944		LaHann	8/10/99	
	AQ	5,990,083		Iqbal et al.	11/23/99	
M.C.H.	AR	2002/0188100	A1	Plamondon et al.	12/12/02	


FOREIGN PATENT DOCUMENTS								
Examiner Initials	Doc. No.	Foreign Patent Document			Name of Patentee or Applicant	Date of Publication	Translation	
		Office	Application or Patent Number	Kind Code			Yes	No**
M.C.H.	AS	WO	98/35691	A1	Proscript, Inc.	8/20/98		
	AT	WO	99/15183	A1	Proscript Inc.	4/1/99		
	AU	WO	00/57887	A1	Glycosyn Pharmaceuticals, Inc.	10/5/00		
M.C.H.	AV	WO	02/059131	A1	Millennium Pharmaceuticals, Inc.	8/1/02		

OTHER - NON PATENT LITERATURE DOCUMENTS									
Examiner Initials		Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.					Translation	
								Yes	No**
MCH		AW	CIECHANOVER, "The Ubiquitin-Proteasome Proteolytic Pathway," <i>Cell</i> , Vol. 79, pp. 13-21 (October 7, 1994)						
		AX	GENNARO, "Remington: The Science and Practice of Pharmacy," 20 <sup>th</sup> Edition, Chapter 42, pp. 802-803 (2000)						
		AY	KIBBE, "Handbook of Pharmaceutical Excipients," 3 <sup>rd</sup> Edition, pp. 324-328 (2000)						
		AZ	KORCEK et al., "Absolute Rate Constants for the Autoxidation of Organometallic Compounds, Part II. Benzylboranes and 1-Phenylethylboranes," <i>J. Chem. Soc., Perkin Trans. II</i> , pp. 242-248 (1972)						
		BA	RICHARDSON et al., "A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma," <i>N. Engl. J. Med.</i> , Vol. 348, No. 26, pp. 2609-2617 (June 2003)						
		BB	SNYDER et al., "Aryl Boronic Acids. II. Aryl Boronic Anhydrides and their Amine Complexes," <i>J. Am. Chem. Soc.</i> , 80, pp. 3611-3615 (1958)						
		BC	STELLA et al., "Development of Parenteral Formulations of Experimental Cytotoxic Agents. I. Rhizoxin (NSC-332598)," <i>International Journal of Pharmaceutics</i> , Vol. 43, pp. 191-199 (1988)						
MCH		BD	WILLIAMS et al., "The Effects of Cooling Rate on Solid Phase Transitions and Associated Vial Breakage Occurring in Frozen Mannitol Solutions," <i>Journal of Parenteral Science &amp; Technology</i> , Vol. 40, No. 4, pp. 135-141 (July-August 1986)						

Examiner Signature	Date Considered 11/21/03
--------------------	--------------------------

- \* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).  
 + An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

+



# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet	2	of	2
-------	---	----	---

Application Number	10/056,567
Filing Date	January 25, 2002
First Named Inventor	Shanker GUPTA
Group Art Unit	1623
Examiner Name	Michael C. Henry
Attorney Docket Number	214980

RECEIVED  
SEP 1 2 2003  
TECH CENTER 1600/2800

[illegible]

12

~~11~~ 11/21/03

- \* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).
- + An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).